The
Latest
The Latest
Video
Field Trip Health: Video Profile
News
PsyBio Therapeutics Retains KCSA Strategic Communications for Investor Relations Services
News
Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial
News
MINDCURE Announces Additional Equity Investment in ATMA
More Articles
FEATURED
MINDCURE Announces Additional Equity Investment in ATMA
News
Havn Life Completes Acquisition of Strategic Manufacturing & Packaging Facility for its Retail Division
News
Core One Labs Vocan Expands Product Commercialization Team
Trending
#
Spotlight
Greg McKee | CEO, Tryp Therapeutics
#
News
NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity
#
News
Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.
#
News
Family of Bob Marley and Silo Wellness Collaborate to Debut Exclusive Worldwide Functional & Psychedelic Mushroom Brand
#
News
Creso Pharma Signs Agreement to Acquire Established Canadian Psychedelics Company Halucenex Life Sciences Inc.
Companies
#
Tryp Therapeutics
NEO
NASDAQ
CSE
TSXV
Private Company
#
Cybin Corp
NEO
NASDAQ
CSE
TSXV
Private Company
#
Field Trip Health
NEO
NASDAQ
CSE
TSXV
Private Company
#
Mydecine Innovations Group
NEO
NASDAQ
CSE
TSXV
Private Company
#
Numinus
NEO
NASDAQ
CSE
TSXV
Private Company
Features
Video
Field Trip Health: Video Profile
News
PsyBio Therapeutics Retains KCSA Strategic Communications for Investor Relations Services
News
Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial
News
MINDCURE Announces Additional Equity Investment in ATMA
© year Psychedelic Finance